Inmolecule Nanotech, S.A.

€3.98As of Sun 8 Nov 2026, 12:00 UTC

EPA:MLINAHealthcare

Country France

PE (Fwd) —

TSR 10Y CAGR —

Div yield —

ROE (6.07%)

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM —

Mkt cap €29.85M

ROIC 0.59%

SE Grade™

—

Value

Quality

Moat

1Y Price

Reference

€4.31

8.17%

(96.70%)

Price above Reference Value

TTM

FYE 31 Dec EUR

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

3.066

Revenue€M

—

1.527

1.981

3.066

3.815

41.68%

—

54.81

Revenue growth%

—

29.67

54.81

24.42

42.24

—

41.03

Gross margin%

—

53.81

79.87

41.03

21.61

53.81

—

1.92

Operating margin%

—

(107.37)

(7.49)

1.92

6.63

(7.49)

—

(14.69)

Net margin%

—

(106.56)

(11.50)

(14.69)

(16.29)

(14.69)

—

P/E ratio (avg)x

—

562.1

EV/EBITx

—

131.1

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

0.59

ROIC%

—

(14.77)

(1.46)

0.59

2.43

(1.46)

—

(6.07)

Return on equity%

—

(19.05)

(2.86)

(6.07)

(8.71)

(6.07)

—

(3.14)

Return on assets%

—

(11.29)

(1.85)

(3.14)

(4.53)

(3.14)

—

(0.06)

EPS€

—

(0.22)

(0.03)

(0.06)

(0.08)

—

(97.81)

EPS growth%

—

86.01

(97.81)

(37.95)

(5.90)

—

0.99

Bookvalue per sh€

—

1.14

0.99

0.91

(6.64%)

—

FCF per share€

—

Dividend per sh€

—

Div yield (avg)%

—

Payout ratio%

—

7.500

Shares (diluted)M

—

7.500

—

◌7.500

—

Buyback yield%

—

0.450

D/E ratiox

—

0.307

0.263

0.450

0.491

0.307

—

33.14

Enterprise value€M

—

33.14

—

1.935

LT debt€M

—

2.617

1.938

1.935

(14.00%)

—

Peers (US$33.52M)

Cap (US$)

Oryzon Genomics S.A.

214.6M

—

Vytrus Biotech, S.A.

115.7M

25.56x

Biotechnology Assets…

16.94M

—

J2KBIO Co., Ltd.

33.07M

7.715x

Capital

TTM

10Y

Leveragex

10.37

14.03

EBIT/Intx

425.5

(11.00)

Own earn%

—

Sh yield%

—

Owners

Insiders/Inst%

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/3

Revenue growth years

—

EPS growth years

—

Dividend streakyrs

Op margin range%

−107–2

$1 testx

—

Incr. ROIC%

—

INMOLECULE NANOTECH, S.A., a biotech company, develops active ingredient nano particles for various applications in the home and personal care, agriculture, aquaculture, and pharmaceutical industries. The company provides Nano-Phyto-Chemistry platform that utilizes plant extracts at the nanometric scale to eliminate infectious germs, including viruses, fungi, bacteria, spores, and mycobacteria, and others.

Growth vs revenue

Latest

Trend

2Y CAGR

Rel growth

Revenue

€3.066M

41.68%

1.00×

Cost of revenue

€1.808M

60.08%

1.28×

Operating expenses

€1.199M

(30.21%)

0.24×

Asset mix

Trend

Other

58.64%

Goodwill & intangibles

40.90%

Cash and investments

0.45%

Reinvestment returns

3Y median

Trend

Reinvestment rate

n/m

Return on capital

(1.46%)

Spread over hurdle

(9.17%)